XML 59 R56.htm IDEA: XBRL DOCUMENT v2.4.1.9
ALLIANCES (AstraZeneca) (Details) (USD $)
3 Months Ended 12 Months Ended
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2017
Dec. 31, 2018
Alliances Statement [Line Items]                              
Number of agreements in alliance 3bmy_NumberofAgreementsinAlliance               3bmy_NumberofAgreementsinAlliance            
The percentage of capital expenditures to be reimbursed by AstraZeneca         50.00%bmy_PercentageOfCapitalExpendituresReimbursedByCollaborationPartner         50.00%bmy_PercentageOfCapitalExpendituresReimbursedByCollaborationPartner          
Net product sales                 $ 11,660,000,000us-gaap_SalesRevenueGoodsNet $ 12,304,000,000us-gaap_SalesRevenueGoodsNet $ 13,654,000,000us-gaap_SalesRevenueGoodsNet        
Alliance and other revenues                 4,219,000,000us-gaap_OtherSalesRevenueNet 4,081,000,000us-gaap_OtherSalesRevenueNet 3,967,000,000us-gaap_OtherSalesRevenueNet        
Total Revenues 4,258,000,000us-gaap_SalesRevenueNet 3,921,000,000us-gaap_SalesRevenueNet 3,889,000,000us-gaap_SalesRevenueNet 3,811,000,000us-gaap_SalesRevenueNet 4,441,000,000us-gaap_SalesRevenueNet 4,065,000,000us-gaap_SalesRevenueNet 4,048,000,000us-gaap_SalesRevenueNet 3,831,000,000us-gaap_SalesRevenueNet 15,879,000,000us-gaap_SalesRevenueNet 16,385,000,000us-gaap_SalesRevenueNet 17,621,000,000us-gaap_SalesRevenueNet        
Deferred income - Cash flow                 613,000,000bmy_IncreaseDecreaseInOtherDeferredRevenue 965,000,000bmy_IncreaseDecreaseInOtherDeferredRevenue 295,000,000bmy_IncreaseDecreaseInOtherDeferredRevenue        
Business divestitures and other proceeds                 3,585,000,000us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested 9,000,000us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested 68,000,000us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested        
Deferred income from alliances included in liabilities related to assets held-for-sale         3,671,000,000bmy_DisposalGroupIncludingDiscontinuedOperationTotalDeferredIncome         3,671,000,000bmy_DisposalGroupIncludingDiscontinuedOperationTotalDeferredIncome          
Deferred income 1,937,000,000us-gaap_DeferredRevenueAndCredits       1,525,000,000us-gaap_DeferredRevenueAndCredits       1,937,000,000us-gaap_DeferredRevenueAndCredits 1,525,000,000us-gaap_DeferredRevenueAndCredits          
AstraZeneca [Member]                              
Alliances Statement [Line Items]                              
Annual limit on development agreement costs                       115,000,000bmy_EstimatedAnnualDevelopmentAgreementCosts
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
115,000,000bmy_EstimatedAnnualDevelopmentAgreementCosts
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
   
Proceeds received at closing for sale of business 2,700,000,000bmy_ProceedsReceivedAtClosingForSaleOfBusiness
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
              2,700,000,000bmy_ProceedsReceivedAtClosingForSaleOfBusiness
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
           
Total contingent regulatory and sales based milestone payments 1,400,000,000bmy_TotalContingentRegulatoryandSalesBasedMilestonePayments
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
              1,400,000,000bmy_TotalContingentRegulatoryandSalesBasedMilestonePayments
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
           
Contingent approval milestones 800,000,000bmy_ContingentApprovalMilestones
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
              800,000,000bmy_ContingentApprovalMilestones
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
           
Total contingent sales based milestones 600,000,000bmy_TotalContingentSalesBasedMilestones
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
              600,000,000bmy_TotalContingentSalesBasedMilestones
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
           
Contingent payments related to transfer of certain assets and businesses 225,000,000bmy_ContingentPaymentsRelatedToTransferOfCertainAssetsAndBusinesses
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
              225,000,000bmy_ContingentPaymentsRelatedToTransferOfCertainAssetsAndBusinesses
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
           
Business sale total consideration received                 3,800,000,000bmy_BusinessSaleTotalConsiderationReceived
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
           
Contingent regulatory milestone consideration received                 700,000,000bmy_ContingentRegulatoryMilestoneConsiderationReceived
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
           
Portion of proceeds allocated to the sale of business                 3,300,000,000bmy_PortionOfProceedsAllocatedToTheSaleOfBusiness
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
           
Portion of proceeds allocated to undelivered elements                 492,000,000bmy_PortionOfProceedsAllocatedToUndeliveredElements
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
           
Total earned royalties                 235,000,000bmy_TotalEarnedRoyalties
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
           
Allocation of goodwill to disposal group                 600,000,000us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
           
Reversal of deferred tax liabilities attributed to inside tax basis of disposal group                 821,000,000bmy_ReversalOfDeferredTaxLiabilitiesAttributedToInsideTaxBasisOfDisposalGroup
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
           
Net product sales                 160,000,000us-gaap_SalesRevenueGoodsNet
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
1,658,000,000us-gaap_SalesRevenueGoodsNet
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
962,000,000us-gaap_SalesRevenueGoodsNet
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
       
Alliance and other revenues                 135,000,000us-gaap_OtherSalesRevenueNet
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
16,000,000us-gaap_OtherSalesRevenueNet
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
10,000,000us-gaap_OtherSalesRevenueNet
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
       
Total Revenues                 295,000,000us-gaap_SalesRevenueNet
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
1,674,000,000us-gaap_SalesRevenueNet
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
972,000,000us-gaap_SalesRevenueNet
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
       
Payments to/(from) alliance partner- Cost of products sold                 (9,000,000)bmy_PaymentsToFromAlliancePartnersRecognizedInCostofProductsSold
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
(25,000,000)bmy_PaymentsToFromAlliancePartnersRecognizedInCostofProductsSold
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
(4,000,000)bmy_PaymentsToFromAlliancePartnersRecognizedInCostofProductsSold
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
       
Payments to/(from) alliance partner - Marketing, selling and administrative                 (6,000,000)bmy_PaymentsToFromAlliancePartnersRecognizedInMarketingSellingAndAdministrative
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
(127,000,000)bmy_PaymentsToFromAlliancePartnersRecognizedInMarketingSellingAndAdministrative
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
(66,000,000)bmy_PaymentsToFromAlliancePartnersRecognizedInMarketingSellingAndAdministrative
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
       
Payments to/(from) alliance partner - Advertising and product promotion                 (2,000,000)bmy_PaymentsToFromAlliancePartnerRecognizedInAdvertisingAndProductPromotion
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
(45,000,000)bmy_PaymentsToFromAlliancePartnerRecognizedInAdvertisingAndProductPromotion
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
(43,000,000)bmy_PaymentsToFromAlliancePartnerRecognizedInAdvertisingAndProductPromotion
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
       
Payments to/(from) alliance partner - Research and development                 (16,000,000)bmy_PaymentsToFromAlliancePartnerRecognizedInResearchAndDevelopment
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
(86,000,000)bmy_PaymentsToFromAlliancePartnerRecognizedInResearchAndDevelopment
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
(25,000,000)bmy_PaymentsToFromAlliancePartnerRecognizedInResearchAndDevelopment
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
       
Provision for restructuring                 (2,000,000)bmy_PaymentsToFromAlliancePartnerRecognizedInProvisionForRestructuring
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
(25,000,000)bmy_PaymentsToFromAlliancePartnerRecognizedInProvisionForRestructuring
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
(21,000,000)bmy_PaymentsToFromAlliancePartnerRecognizedInProvisionForRestructuring
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
       
Royalties                 (192,000,000)bmy_BusinessSaleRoyaltyIncome
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
           
Transitional services                 (90,000,000)bmy_AllianceTransitionalServices
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
           
Gain on sale of business   292,000,000us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
            (536,000,000)us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
           
Deferred income - Cash flow                 315,000,000bmy_IncreaseDecreaseInOtherDeferredRevenue
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
215,000,000bmy_IncreaseDecreaseInOtherDeferredRevenue
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
3,547,000,000bmy_IncreaseDecreaseInOtherDeferredRevenue
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
       
Business divestitures and other proceeds                 3,495,000,000us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
           
AstraZeneca [Member] | Amylin Acquisition [Member]                              
Alliances Statement [Line Items]                              
Payment made by an alliance partner to enter into an alliance agreement                     3,600,000,000bmy_PaymentToEnterIntoCollaborationAgreement
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ bmy_AlliancesAndCollaborationsAxis
= bmy_AmylinAcquisitionMember
       
Payment made by an alliance partner to establish equal governance rights over certain key strategic and financial decisions regarding the alliance                   135,000,000bmy_PaymentMadeToEstablishEqualCollaborationGovernanceRights
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ bmy_AlliancesAndCollaborationsAxis
= bmy_AmylinAcquisitionMember
         
Useful life of property, plant and equipment                   15 years 0 months 0 days          
AstraZeneca [Member] | Upfront, milestone and other licensing payments [Member]                              
Alliances Statement [Line Items]                              
Deferred income from alliances included in liabilities related to assets held-for-sale         3,671,000,000bmy_DisposalGroupIncludingDiscontinuedOperationTotalDeferredIncome
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ bmy_AlliancesAndCollaborationsAxis
= bmy_UpfrontMilestoneAndOtherLicensingPaymentsMember
        3,671,000,000bmy_DisposalGroupIncludingDiscontinuedOperationTotalDeferredIncome
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ bmy_AlliancesAndCollaborationsAxis
= bmy_UpfrontMilestoneAndOtherLicensingPaymentsMember
         
AstraZeneca [Member] | Assets Not Yet Transferred to Alliance Partner [Member]                              
Alliances Statement [Line Items]                              
Deferred income 176,000,000us-gaap_DeferredRevenueAndCredits
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ bmy_AlliancesAndCollaborationsAxis
= bmy_AssetsNotYetTransferredtoAlliancePartnerMember
              176,000,000us-gaap_DeferredRevenueAndCredits
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ bmy_AlliancesAndCollaborationsAxis
= bmy_AssetsNotYetTransferredtoAlliancePartnerMember
           
AstraZeneca [Member] | Services Not Yet Performed For Alliance Partner [Member]                              
Alliances Statement [Line Items]                              
Deferred income 226,000,000us-gaap_DeferredRevenueAndCredits
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ bmy_AlliancesAndCollaborationsAxis
= bmy_ServicesNotYetPerformedForAlliancePartnerMember
              226,000,000us-gaap_DeferredRevenueAndCredits
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ bmy_AlliancesAndCollaborationsAxis
= bmy_ServicesNotYetPerformedForAlliancePartnerMember
           
AstraZeneca [Member] | Onglyza, Kombiglyze and Forxiga [Member]                              
Alliances Statement [Line Items]                              
Royalty rate sales threshold - Minimum 500,000,000bmy_RoyaltyratesalesthresholdMinimum
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeAndForxigaMember
              500,000,000bmy_RoyaltyratesalesthresholdMinimum
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeAndForxigaMember
           
Royalty rate sales threshold - Maximum 500,000,000bmy_RoyaltyratesalesthresholdMaximum
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeAndForxigaMember
              500,000,000bmy_RoyaltyratesalesthresholdMaximum
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeAndForxigaMember
           
AstraZeneca [Member] | Onglyza Kombiglyze [Member] | Upfront, milestone and other licensing payments [Member]                              
Alliances Statement [Line Items]                              
Total upfront, milestone and other licensing payments received to date         300,000,000bmy_TotalUpfrontLicensingAndMilestoneReceipts
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ bmy_AlliancesAndCollaborationsAxis
= bmy_UpfrontMilestoneAndOtherLicensingPaymentsMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeMember
        300,000,000bmy_TotalUpfrontLicensingAndMilestoneReceipts
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ bmy_AlliancesAndCollaborationsAxis
= bmy_UpfrontMilestoneAndOtherLicensingPaymentsMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeMember
         
AstraZeneca [Member] | Amylin Related Products [Member]                              
Alliances Statement [Line Items]                              
Royalty rate on net sales                       2.00%bmy_RoyaltyRateOnNetSales
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_AmylinRelatedProductsMember
2.00%bmy_RoyaltyRateOnNetSales
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_AmylinRelatedProductsMember
5.00%bmy_RoyaltyRateOnNetSales
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_AmylinRelatedProductsMember
 
Cost of products sold - Amortization of deferred income                   (307,000,000)bmy_AmortizationIncomeOfUpfrontPaymentsRecognizedInCostOfProductsSold
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_AmylinRelatedProductsMember
(126,000,000)bmy_AmortizationIncomeOfUpfrontPaymentsRecognizedInCostOfProductsSold
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_AmylinRelatedProductsMember
       
AstraZeneca [Member] | Farxiga [Member] | Upfront, milestone and other licensing payments [Member]                              
Alliances Statement [Line Items]                              
Total upfront, milestone and other licensing payments received to date         250,000,000bmy_TotalUpfrontLicensingAndMilestoneReceipts
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ bmy_AlliancesAndCollaborationsAxis
= bmy_UpfrontMilestoneAndOtherLicensingPaymentsMember
/ us-gaap_ProductOrServiceAxis
= bmy_DapagliflozinMember
        250,000,000bmy_TotalUpfrontLicensingAndMilestoneReceipts
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ bmy_AlliancesAndCollaborationsAxis
= bmy_UpfrontMilestoneAndOtherLicensingPaymentsMember
/ us-gaap_ProductOrServiceAxis
= bmy_DapagliflozinMember
         
AstraZeneca [Member] | Onglyza Kombiglyze Farxiga [Member]                              
Alliances Statement [Line Items]                              
Other (income)/expense - Amortization of deferred income                 (80,000,000)bmy_AmortizationIncomeMilestonePayments
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeForxigaMember
(31,000,000)bmy_AmortizationIncomeMilestonePayments
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeForxigaMember
(38,000,000)bmy_AmortizationIncomeMilestonePayments
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeForxigaMember
       
AstraZeneca [Member] | Onglyza Kombiglyze Farxiga And Amylin Related Products [Member]                              
Alliances Statement [Line Items]                              
Cost of products sold - Profit sharing                 $ 79,000,000bmy_AllianceProfitSharingExpense
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeForxigaAndAmylinRelatedProductsMember
$ 673,000,000bmy_AllianceProfitSharingExpense
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeForxigaAndAmylinRelatedProductsMember
$ 425,000,000bmy_AllianceProfitSharingExpense
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeForxigaAndAmylinRelatedProductsMember
       
AstraZeneca [Member] | Bydureon [Member]                              
Alliances Statement [Line Items]                              
Useful life of intangible asset                   13 years 0 months 0 days          
AstraZeneca [Member] | Byetta [Member]                              
Alliances Statement [Line Items]                              
Useful life of intangible asset                   7 years 0 months 0 days          
AstraZeneca [Member] | Symlin [Member]                              
Alliances Statement [Line Items]                              
Useful life of intangible asset                   9 years 0 months 0 days          
AstraZeneca [Member] | Myalept [Member]                              
Alliances Statement [Line Items]                              
Useful life of intangible asset                   12 years 0 months 0 days          
Maximum [Member] | AstraZeneca [Member] | Onglyza, Kombiglyze and Forxiga [Member]                              
Alliances Statement [Line Items]                              
Royalty rate on net sales                 44.00%bmy_RoyaltyRateOnNetSales
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeAndForxigaMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
    27.00%bmy_RoyaltyRateOnNetSales
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeAndForxigaMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
35.00%bmy_RoyaltyRateOnNetSales
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeAndForxigaMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
12.00%bmy_RoyaltyRateOnNetSales
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeAndForxigaMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
25.00%bmy_RoyaltyRateOnNetSales
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeAndForxigaMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
Maximum [Member] | AstraZeneca [Member] | Amylin Related Products [Member]                              
Alliances Statement [Line Items]                              
Royalty rate on net sales                             12.00%bmy_RoyaltyRateOnNetSales
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_AmylinRelatedProductsMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
Minimum [Member] | AstraZeneca [Member] | Onglyza, Kombiglyze and Forxiga [Member]                              
Alliances Statement [Line Items]                              
Royalty rate on net sales                 3.00%bmy_RoyaltyRateOnNetSales
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeAndForxigaMember
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
    9.00%bmy_RoyaltyRateOnNetSales
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeAndForxigaMember
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
7.00%bmy_RoyaltyRateOnNetSales
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeAndForxigaMember
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
12.00%bmy_RoyaltyRateOnNetSales
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeAndForxigaMember
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
14.00%bmy_RoyaltyRateOnNetSales
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_OnglyzaKombiglyzeAndForxigaMember
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
Minimum [Member] | AstraZeneca [Member] | Amylin Related Products [Member]                              
Alliances Statement [Line Items]                              
Royalty rate on net sales                             5.00%bmy_RoyaltyRateOnNetSales
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_AstraZenecaMember
/ us-gaap_ProductOrServiceAxis
= bmy_AmylinRelatedProductsMember
/ us-gaap_RangeAxis
= us-gaap_MinimumMember